A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

• Status: Recruiting
• Trial end date: 2023-12-05
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

For the idiopathic pulmonary fibrosis (IPF) Cohort

• Diagnosis of IPF within 7 years

• Female and males ≥ 40 years of age

For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort

• Evidence of progressive ILD within the 24 months before screening

• Female and male ≥ 21 years of age.

Exclusion Criteria:

• Women of childbearing potential (WOCBP)

• Active Smokers

• Patients with current malignancy

• History of allergy to BMS-986278 or related compounds

Other protocol-defined inclusion/exclusion criteria apply